Compare VERU & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VERU | SCWO |
|---|---|---|
| Founded | 1971 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Environmental Services |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 49.4M |
| IPO Year | 1996 | 2022 |
| Metric | VERU | SCWO |
|---|---|---|
| Price | $2.30 | $2.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.67 | N/A |
| AVG Volume (30 Days) | ★ 192.8K | 33.5K |
| Earning Date | 08-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | ★ $16,296,958.00 | $215,037.00 |
| Revenue This Year | N/A | $25,290.98 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.05 | $0.19 |
| 52 Week High | $7.33 | $5.80 |
| Indicator | VERU | SCWO |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 36.21 |
| Support Level | $2.12 | $2.34 |
| Resistance Level | $2.78 | $2.81 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 28.13 | 3.30 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
374Water Inc is a cleantech and environmental services company developing SCWO for the destruction of organic waste streams within the municipal, federal, and industrial markets. It offers its proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Its AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including forever chemicals into inert and recoverable resources including water, minerals, and heat energy.